Coherus Oncology Revenue Misses in Q1 2026 – Key Study Data Expected Mid-2026
This article was created with the help of artificial intelligence.
Key Takeaways
- Coherus Oncology reported Q1 2026 revenues of $12.3 million on May 11, 2026, missing the analyst estimate of $14.3 million.
- Adjusted loss per share was $0.25, beating expectations of $0.27 by 7.4%.
- LOQTORZI revenues grew 61% year-over-year to $11.8 million in the first quarter of 2026.
- Coherus expects important clinical data releases mid-2026 for pipeline candidates Casdozokitug and Tagmokitug.
- Current liquidity is sufficient for two to three quarters at the current cash burn rate, according to analyst estimates.
Coherus Oncology (NASDAQ: CHRS) reported on May 11, 2026 total revenues of $12.3 million for the first quarter of 2026, falling short of analyst estimates of $14.3 million. The biosimilars and oncology therapeutics-focused biotechnology company from Redwood City, California, reported a better-than-expected adjusted loss per share.
Results Below Expectations Despite LOQTORZI Growth
Adjusted loss per share in the first quarter of 2026 was $0.25, performing 7.4% better than the analyst estimate of $0.27, as Coherus reported on May 11, 2026. Compared to the same quarter of the prior year, when the loss was $0.35 per share, the result improved by 28.6%.
The lead product LOQTORZI – a biosimilar for treating certain cancers – generated revenues of $11.8 million in the first quarter of 2026. This represents 61% growth compared to the prior year period. Despite this development, the company's total revenues remained significantly below market expectations.
Pipeline Progress and Expected Study Data
Coherus is working on several candidates in clinical development. For mid-2026, the company expects important data releases on two pipeline products: Casdozokitug and Tagmokitug. Both active ingredients are in advanced study phases for treating oncologic indications.
The upcoming data releases are considered important milestones for the company's further development. They are intended to provide insights into the efficacy and safety of the candidates and form the basis for potential regulatory applications.
Liquidity Position and Financing Needs
An analysis published by SeekingAlpha on May 13, 2026 estimates that Coherus's current liquidity will be sufficient for two to three quarters at the current cash burn rate. According to this assessment, the company could require additional financing before the critical clinical milestones materialize in mid-year.
The assessment points to the typical challenge for biotech companies in the clinical development phase: high expenses for research and studies are offset by limited revenues from already marketed products. LOQTORZI, as the primary source of income, has not yet been able to fully offset development costs.
Earnings Call and Company Outlook
Coherus Oncology held a conference call on May 11, 2026 at 5:00 p.m. EDT to discuss quarterly results. Carrie Graham, Vice President of Investor Relations, participated in the conference. The company discussed business developments and answered analyst questions about future strategy.
The coming months are considered critical for Coherus: the expected clinical data for Casdozokitug and Tagmokitug in mid-2026 will show whether the company can successfully advance its pipeline. At the same time, management must keep an eye on the capital situation and possibly explore financing options if necessary.